What Does a Psilocybin-Assisted Therapy Session Actually Involve, from Screening to Integration?

Psilocybin-assisted therapy (PAT) is not simply taking a drug. It is a structured, multi-phase psychotherapeutic process that combines the administration of a psychedelic compound with comprehensive psychological support . This guide provides a detailed walkthrough of what a PAT session involves in Australia, from the initial screening to the final integration sessions, within the country’s strictly regulated framework.

The Regulatory Context: Safety First

Before describing the therapeutic process, it is essential to understand the strict legal and safety framework. In Australia, PAT is only available for treatment-resistant depression (TRD) through the Therapeutic Goods Administration’s (TGA) Authorised Prescriber (AP) scheme . Only specialist psychiatrists registered with the Medical Board of Australia and the Royal Australian and New Zealand College of Psychiatrists (RANZCP) can prescribe psilocybin . These psychiatrists must develop a clinical protocol, obtain approval from a registered Human Research Ethics Committee (HREC), and receive TGA authorisation .

Key safety stipulations include:

• Treatment must occur in a medically supervised environment .
• Patients cannot take the medicine home .
• Only pharmaceutical-grade psilocybin is permitted; the use of mushrooms or their extracts is not allowed .
• A “therapy dyad” of at least two therapists must be present during the dosing session .

Phase 1: Screening and Assessment

The therapeutic journey begins long before any medicine is administered. A thorough screening process ensures that PAT is appropriate and safe for the individual .

1. Initial Referral and Psychiatric Assessment:
The process typically starts with a referral from a General Practitioner to a psychiatrist who is or can become an Authorised Prescriber. The psychiatrist conducts a comprehensive assessment to confirm the diagnosis of TRD. This involves reviewing the patient’s full psychiatric history, treatment responses, and confirming that they have exhausted all other TGA-approved treatment options .

2. Medical and Psychiatric Screening:
The psychiatrist conducts a detailed medical and psychiatric evaluation to identify any contraindications . Key exclusion criteria often include a personal or first-degree family history of psychosis, as well as certain medical conditions that could pose a risk . This screening also involves reviewing current medications and planning for any necessary “washout” periods or tapering of contraindicated drugs .

3. Informed Consent:
A crucial part of the screening process involves obtaining informed consent. The psychiatrist must thoroughly explain the treatment’s purpose, what is involved, and the potential psychological and physical risks. This is a formal process with detailed consent forms, ensuring the patient fully understands the experimental nature of the unapproved medicine and the commitment required .

Phase 2: Preparation

Once approved, the patient enters the preparation phase. This is a vital period for building trust with the therapy team and establishing a foundation for the psychedelic experience .

1. Building the Therapeutic Alliance:
Preparation sessions (often 2-3 sessions) are conducted with the treating therapists . The goal is to establish a safe, trusting relationship. The patient is encouraged to share their life story, struggles, and hopes for the treatment.

2. Setting Intentions and Psychoeducation:
The therapists provide comprehensive psychoeducation about the process. They explain what the patient might experience during the dosing session—including altered perceptions, emotional shifts, and the potential for challenging moments—and offer anxiety management strategies . The patient is encouraged to set a personal “intention” for the session, a mental focus or goal to guide their journey. The focus is also on preparing the patient’s “set and setting,” meaning their internal mindset and the external physical and social environment .

Phase 3: The Dosing Session

This is the central and most distinctive component of PAT. It is a carefully supported clinical session where the patient takes the psilocybin in a safe, comfortable environment .

1. Administration and Setting:
The treatment takes place in a medically supervised facility that meets TGA requirements, including being near (within 15 minutes of) an accredited healthcare facility with an emergency department . The room is designed to be comfortable and calming, often with music and a supportive, non-clinical aesthetic. A standard dose in clinical settings is typically 25 mg of pharmaceutical-grade psilocybin, given orally . The AP psychiatrist is responsible for administering the medicine and must be present during the session .

2. The Role of the Therapy Team:
The TGA requires a “therapy dyad” during the dosing session. This means at least two trained therapists are with the patient at all times . This team provides continuous support, helping the patient navigate their experience, managing any distress, and ensuring their physical and emotional safety. The presence of a second therapist is a key safety and therapeutic measure .

3. The Experience:
The psilocybin session itself can last for several hours . During this time, patients may experience profound personal introspection, emotional breakthroughs, memories, or feelings of connection and insight . The therapists adopt a supportive, non-directive stance, allowing the patient’s own internal process to unfold while remaining present to offer reassurance if needed. Professor Suresh Sundram of Monash University notes that “once someone takes a therapeutic or a high dose of a psychedelic agent, where the medicine takes them will be their own personal journey” .

Phase 4: Integration

The therapeutic process does not end when the acute effects of the medicine wear off. Integration is perhaps the most critical phase for translating the profound experience into lasting change .

1. Follow-Up Therapy Sessions:
In the days and weeks following the dosing session, the patient attends a series of integration sessions with their therapists (often 1-2 sessions) . The purpose is to help the patient process and make sense of their experience.

2. Applying Insights to Daily Life:
The therapists help the patient connect the insights, emotions, and new perspectives gained during the session to their everyday life and ongoing mental health challenges. The goal is to integrate these learnings into their personal narrative, helping them make positive changes in their behaviour, relationships, and self-understanding. This is the crucial bridge between the psychedelic experience and lasting therapeutic benefit.

Conclusion

A psilocybin-assisted therapy session in Australia is a comprehensive and regulated process, far beyond simply taking a medication. It is a journey that begins with rigorous screening, proceeds through careful preparation, involves a supported and profound experience, and culminates in the crucial work of integration. This structured approach is designed to maximise safety and therapeutic benefit for patients with treatment-resistant depression, who have exhausted other treatment options.